-$0.18 EPS Expected for OncoSec Medical Inc (ONCS) This Quarter
Wall Street brokerages expect that OncoSec Medical Inc (NASDAQ:ONCS) will announce ($0.18) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for OncoSec Medical’s earnings. OncoSec Medical posted earnings per share of ($0.24) during the same quarter last year, which would suggest a positive year over year growth rate of 25%. The company is expected to announce its next quarterly earnings results on Friday, March 8th.
On average, analysts expect that OncoSec Medical will report full-year earnings of ($0.70) per share for the current year, with EPS estimates ranging from ($0.74) to ($0.65). For the next financial year, analysts anticipate that the company will report earnings of ($0.84) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow OncoSec Medical.
OncoSec Medical (NASDAQ:ONCS) last issued its quarterly earnings data on Friday, December 14th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.06.
Several large investors have recently bought and sold shares of ONCS. BlackRock Inc. raised its position in shares of OncoSec Medical by 1,303.5% in the second quarter. BlackRock Inc. now owns 238,940 shares of the biotechnology company’s stock worth $330,000 after buying an additional 221,916 shares in the last quarter. 683 Capital Management LLC purchased a new stake in OncoSec Medical during the second quarter valued at about $414,000. Finally, Millennium Management LLC raised its position in OncoSec Medical by 19.5% during the second quarter. Millennium Management LLC now owns 1,195,315 shares of the biotechnology company’s stock valued at $1,650,000 after purchasing an additional 194,739 shares in the last quarter. Hedge funds and other institutional investors own 11.49% of the company’s stock.
Shares of NASDAQ ONCS traded up $0.02 during trading on Friday, reaching $0.70. The company had a trading volume of 9,300 shares, compared to its average volume of 379,027. OncoSec Medical has a 12 month low of $0.54 and a 12 month high of $2.21.
About OncoSec Medical
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.
Recommended Story: Cost of equity and a company’s balance sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.